Le Lézard
Classified in: Health
Subjects: NPT, SVY, WOM, STP, AVO

Population Institute's Annual Report Card Shows Reproductive Health and Rights at a Tipping Point: U.S. gets an "F"


WASHINGTON, March 2, 2021 /PRNewswire/ -- Today the non-profit Population Institute released its 50 State Report Card on Reproductive Health and Rights. The most comprehensive assessment of its kind, it annually tracks multiple indicators of reproductive health and rights, including access to family planning, sex education, and abortion services, across each state.  

The new report card finds a large divide between states that are prioritizing reproductive health and rights and access to reproductive health services, vs. those that are seeking to curtail them. Five states got an "A," 23 states failed, and for the second year in a row, the U.S. as a whole also failed.

The Biden-Harris administration will strive to improve reproductive health and rights at the federal level. But the reshaping of the federal judiciary by the Trump-Pence Administration, and persistent hostility to family planning in Republican-controlled state governments, stands to undermine Americans' reproductive health, rights and justice for decades to come. 

"We're at a turning point," said Jennie Wetter, the Population Institute's director of public policy. "The Biden-Harris administration faces a steep uphill battle to reverse the sharp decline in reproductive health and rights over the last four years."

Amid the pandemic, "anti-choice" advocates sought to restrict access to reproductive health care. In several states they denied access to abortion services by classifying them as non-essential health care, while the Trump administration sought to require people seeking medication abortion first see a doctor in person, putting their health needlessly at risk.

While courts have blocked many attacks in recent years, Wetter said, "Anti- choice advocates will keep trying to restrict access to reproductive health services. The Biden-Harris administration has a lot of work to do. Not everything will be easily or quickly fixed."

Taking advantage of the new make-up of the Supreme Court, anti-choice advocates are expected to file legal challenges to any new legislative or regulatory changes. "If they succeed," Wetter warned, "the people most impacted will be underserved populations, including low-income people, Black people, other communities of color, young people, and the LGBTQ+ community. Existing disparities in access to reproductive health services will worsen. Despite the new Congress and the new administration, the fight over affordable access to sexual and reproductive health care is far from over."

Source: Population Institute https://www.populationinstitute.org/

Contact:  Stephen Kent, [email protected] 914-589-5988

SOURCE Population Institute


These press releases may also interest you

at 07:10
Can-Fite BioPharma Ltd. , a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced financial results and clinical updates for the twelve months ended...

at 07:10
Kelonia Therapeutics, a biotech company revolutionizing in vivo gene delivery, today announced the appointments of global leaders in cell therapy and drug development, Kristen Hege, M.D., and Mathai Mammen, M.D., Ph.D., to its board of directors....

at 07:05
Aldeyra Therapeutics, Inc. (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the clinical development plan intended to enable...

at 07:05
Mythic Therapeutics, a clinical-stage biotechnology company committed to the development of next-generation antibody-drug conjugate (ADC) therapies for the treatment of a wide range of cancers, announced that George Eliades, Ph.D., has joined the...

at 07:05
Seres Therapeutics, Inc. ("Seres" or the "Company"), a leading microbiome therapeutics company, today announced that on March 25, 2024, the Compensation and Talent Committee of Seres' board of directors granted inducement equity grants covering an...

at 07:05
Gilead Sciences, Inc. and Xilio Therapeutics, Inc. today announced an exclusive license agreement to develop and commercialize Xilio's Phase 1 tumor-activated IL-12 program, XTX301. Xilio Therapeutics is a clinical-stage biotechnology company...



News published on and distributed by: